Aceclofex SR

Description

💊 Aceclofex SR – Aceclofenac 200 mg

Manufacturer: SinoHealth Pharmaceuticals LTD

---

1. Presentation:

Each film-coated sustained-release tablet contains:
➡️ Aceclofenac BP 200 mg

Available as film-coated sustained-release tablets for oral administration.

---

2. Description:

Aceclofex SR is a non-steroidal anti-inflammatory drug (NSAID) with potent anti-inflammatory and analgesic properties.

Its mode of action is primarily based on the inhibition of prostaglandin synthesis, which reduces pain, swelling, and inflammation.

Aceclofex SR is a potent inhibitor of cyclooxygenase (COX) enzymes, responsible for prostaglandin production. It also contributes to cartilage matrix (glycosaminoglycan) synthesis, supporting joint health.

---

3. Indications:

Aceclofex SR is indicated for the relief of pain and inflammation in both acute and chronic conditions, including:

• Osteoarthritis

• Rheumatoid arthritis

• Ankylosing spondylitis

• Dental pain

• Post-traumatic pain

• Low back pain

• Gynecological pain

---

4. Dosage & Administration:

Adults:
The recommended dose is 200 mg once daily.

Children:
No clinical data is available on the use of aceclofenac in children.

Elderly:
Pharmacokinetics are not significantly altered in elderly patients; no dose adjustment is generally required.

Renal Insufficiency:
No dosage modification is necessary in patients with mild renal impairment.

Hepatic Insufficiency:
In patients with hepatic impairment, an initial dose of 100 mg daily is recommended.

---

5. Side Effects:

Aceclofex SR is generally well-tolerated. Most side effects are mild and reversible, including:

• Gastrointestinal disorders (dyspepsia, abdominal pain, nausea, diarrhea)

• Dizziness

• Skin reactions (rash, pruritus)

• Occasional elevation of hepatic enzymes

• Rare increase in serum creatinine

---

6. Precautions:

• Administer with caution in patients with gastrointestinal disorders, history of peptic ulcer, ulcerative colitis, Crohn’s disease, hepatic porphyria, or coagulation disorders.

• Monitor patients with severe hepatic impairment.

• Avoid concurrent use with other NSAIDs or alcohol.

---

7. Use in Pregnancy & Lactation:

Pregnancy:
Not recommended unless necessary; use the lowest effective dose. Avoid during the third trimester.

Lactation:
Use should be avoided unless benefits to the mother outweigh risks to the child.

---

8. Overdose:

Limited human data is available.

Management:

• Prevent absorption via gastric lavage and activated charcoal if ingestion is recent.

• Provide supportive and symptomatic care for any complications.

---

9. Commercial Pack:

Box of 3 × 10’s film-coated sustained-release tablets